Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.
Twenty four chronic psychotic patients were assigned at random to bromperidol or haloperidol. The mean dose for bromperidol was 4 to 8 mg in one intake in the morning and for haloperidol 4 mg given twice a day. Regular evaluation was performed by BPRS, global clinical impression, side-effects scale, hematological and biochemical screening. It appears that bromperidol is a potent antipsychotic drug with a duration of 24 h. Compared to haloperidol, it favours social integration by a mild but definite activating property. No major side-effects were observed.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*
D006220:Haloperidol